Gynecological Health Company Daye Receives FDA Clearance For Its Nude Tampon

Gynecological health startup Daye, best known for having invented the world’s first cannabidiol (CBD) tampon, has obtained FDA 510(k) clearance for its Nude Tampon ahead of its U.S. launch next month. 

Daye’s Nude Tampon is a game-changer for women, girls and assigned female at birth (AFAB) individuals. It offers them a new level of care during their menstrual cycle. Daye is the only brand to clinically test their tampons with human clinical trials, and its Nude tampon is the only tampon on the market sanitised with gamma irradiation, which adds additional protection for tampon customers against microbial contamination.

It is also 100% organic, made using ethically sourced materials, free of dyes, pesticides and fragrances. It is free of plastic, rayon, chlorine bleach, dioxin, phthalates and fragrances – all of which have been commonly found in mainstream tampons. It is also housed in a sustainable sugarcane applicator and a water-soluble, flushable, ocean-safe wrapper, allowing Daye to reduce non-recyclable plastic waste and promote greener periods.

Daye’s Nude Tampon features an innovative protective sleeve, meaning users do not need to worry about shedding tampon fibers which can cause vaginal infections like thrush and BV. With its organic protective sleeve, the Nude Tampon ensures no bits of your tampon overstay their welcome.

“This achievement marks a pivotal moment in our mission to enhance the health and well-being of women and AFAB individuals. Our Nude Tampon underwent rigorous evaluation before its approval, demonstrating the product’s safety and performance,” said Valentina Milanova, founder and CEO of Daye.

“This milestone validates the extensive research, development, and testing that have gone into creating a product that not only meets the highest medical standards but also addresses the menstrual care needs of people with periods,” Milanova added. “What sets the Nude Tampon apart is our commitment to safety (Daye is certified to GMP and ISO1345, and we sanitise and produce our tampons in clean rooms) and sustainability.

“Next, we will introduce a water-soluble tampon applicator. Daye is also working on a Pain-Relieving Tampon for chronic pelvic pain and on a Diagnostic Tampon to help increase access to at-home vaginal health screenings. These additional tampon variants are based on the foundation that the Nude Tampon provides,” Milanova said.

SourceDaye
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

Tabrecta is the first FDA-approved therapy to treat non small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).
The Cor® TRICUSPID ECM® valve has been successfully implanted in the 11th patient enrolled in the expansion by Dr. Marc Gerdisch, Chief of Cardiothoracic Surgery at Franciscan Health Heart Center in Indianapolis, Indiana & principal investigator for the adult component of the study.
Thirona notes LungQ 3.0.0 builds on 10 years of clinical trials and 200+ publications to deliver advanced segmentation of pulmonary segments and subsegments.
The Zeta Surgical Cranial Navigation System is a mixed-reality navigation system for neurosurgery, providing surgeons with "GPS-like" guidance with millimetric accuracy in real-time. Zeta's computer vision engine ensures maintained accuracy by automatically registering multiple times a second, accounting for patient movement, and allowing for awake and non-immobilized use in both operative and extra-operative settings.
The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.

By using this website you agree to accept Medical Device News Magazine Privacy Policy